Topic

Mike Hennessy Jr. is the President and CEO of 

Articles

It has been a long wait, but for Alzheimer’s at least, this is the beginning of renewed hope.

Renewed Hope for Alzheimer’s

A proposed database includes key information about critical drugs, such as the country of origin and quantity, so supply chain weaknesses can be identified. 

Supply Chain Securities

The debate surrounding drug pricing changes rages on.

Drug Pricing’s Static Changes

COVID-19 has raised the specter of pandemic planning and the question of what can be done now to prevent future disaster.

Governance of Future Pandemics

The engine that drives pharmaceuticals forward, its workforce, is now very low on fuel.

Young Pups and Leopards

Direct-to-consumer drug advertising has developed as a cottage industry which has been used to increase prescriptions immensely. 

Who’s Got Game?

That wave beginning to crash over PhRMA’s gunwales may well emanate from a startup mindset, rather than Big Pharma or government policy pundits.

Subsurface Currents

The restraint to not target solely the major disease groups has provided good proportion and balance for our industry.

Proportion,  Balance, and Restraint

Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.

Paradigm Shift

Science news can be just so weird, or weirdly useful, that everything else recedes as we ponder whether it is true and what consequences it might bring.

From the CEO